000170464 001__ 170464
000170464 005__ 20240229133714.0
000170464 0247_ $$2doi$$a10.1111/ene.15082
000170464 0247_ $$2pmid$$apmid:34435414
000170464 0247_ $$2ISSN$$a1351-5101
000170464 0247_ $$2ISSN$$a1468-1331
000170464 0247_ $$2ISSN$$a1471-0552
000170464 0247_ $$2altmetric$$aaltmetric:112423430
000170464 037__ $$aDKFZ-2021-01957
000170464 041__ $$aEnglish
000170464 082__ $$a610
000170464 1001_ $$00000-0002-6612-4749$$aHedström, Anna Karin$$b0
000170464 245__ $$aLow sun exposure acts synergistically with high EBNA-1 antibody levels in MS etiology.
000170464 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2021
000170464 3367_ $$2DRIVER$$aarticle
000170464 3367_ $$2DataCite$$aOutput Types/Journal article
000170464 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642423234_11680
000170464 3367_ $$2BibTeX$$aARTICLE
000170464 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000170464 3367_ $$00$$2EndNote$$aJournal Article
000170464 500__ $$a2021 Dec;28(12):4146-4152
000170464 520__ $$aAmong multiple sclerosis (MS) patients, an association has been observed between low levels of vitamin D and high Epstein-Barr nuclear antigen 1 (EBNA-1) antibody levels. However, whether sun exposure/vitamin D moderates the role of Epstein-Barr virus infection in MS etiology is unclear. We aimed to investigate potential synergistic effects between low sun exposure and elevated EBNA-1 antibody levels regarding MS risk.We used a population-based case-control study involving 2017 incident cases of MS and 2443 matched controls. We used logistic regression models to calculate odds ratios of MS with 95% confidence intervals (CI) in subjects with different sun exposure habits and EBNA-1 status. Potential interaction on the additive scale was evaluated by calculating the attributable proportion due to interaction (AP).Low sun exposure acted synergistically with high EBNA-1 antibody levels (AP 0.2, 95% CI 0.03-0.3) in its association to increased MS risk. The interaction was present regardless of HLA-DRB1*15:01 status.Low sun exposure may either directly, or indirectly by affecting vitamin D levels, synergistically reinforce pathogenic mechanisms, such as aspects of the adaptive immune response, related to MS risk conveyed by EBV infection.
000170464 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000170464 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000170464 7001_ $$aHuang, Jesse$$b1
000170464 7001_ $$0P:(DE-He78)b1326dc42cbbc5f92b10fe5f254f0bc2$$aBrenner, Nicole$$b2$$udkfz
000170464 7001_ $$0P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aButt, Julia$$b3$$udkfz
000170464 7001_ $$aKockum, Ingrid$$b4
000170464 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b5$$udkfz
000170464 7001_ $$aOlsson, Tomas$$b6
000170464 7001_ $$aAlfredsson, Lars$$b7
000170464 773__ $$0PERI:(DE-600)2020241-6$$a10.1111/ene.15082$$gp. ene.15082$$n12$$p4146-4152$$tEuropean journal of neurology$$v28$$x1351-5101$$y2021
000170464 909CO $$ooai:inrepo02.dkfz.de:170464$$pVDB
000170464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b1326dc42cbbc5f92b10fe5f254f0bc2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000170464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000170464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000170464 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000170464 9141_ $$y2021
000170464 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-27$$wger
000170464 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NEUROL : 2019$$d2021-01-27
000170464 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-27
000170464 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-27
000170464 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-27
000170464 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-27
000170464 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-27
000170464 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000170464 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-27
000170464 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-27
000170464 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000170464 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000170464 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-27
000170464 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-27
000170464 9201_ $$0I:(DE-He78)F022-20160331$$kF022$$lInfektionen und Krebs-Epidemiologie$$x0
000170464 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x1
000170464 980__ $$ajournal
000170464 980__ $$aVDB
000170464 980__ $$aI:(DE-He78)F022-20160331
000170464 980__ $$aI:(DE-He78)F020-20160331
000170464 980__ $$aUNRESTRICTED